GSK’s Tanzeum Once-Weekly GLP-1 To Launch In Third Quarter
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA requires post-marketing studies to identify any cases of medullary thyroid cancer related to the drug and evaluate cardiovascular risk; GSK touts Tanzeum’s sustained glycemic effect, tolerability and its potential use as an alternative to insulin.